Michael W. Konstan - Concepedia

Author

Michael W. Konstan

Also Known As

Accurso, Frank J., Amin, Raouf S, Drumm, Mitchell L., Durie, Peter R., Khan, Umer, M KONSTAN, M Konstan, M W Konstan, M. Konstan, M. W. Konstan

328

Publications

25.8K

Citations

H-Index

122

Concepts

All Affiliations

Case Western Reserve University Rainbow Babies & Children's Hospital University School University of Colorado Denver University of Arizona

About

Michael W. Konstan is an author at Case Western Reserve University specializing in medicine, pulmonary fibrosis, and pulmonary disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	78	8.7K
2	Public Health	8	8	674
3	Health Sciences	2	2	405
4	Education	1	1	22
5	Engineering	1	1	14

Michael W. Konstan

175

Publications

22.4K

Citations

H-Index

Page 1

	Year	Citations
A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation Bonnie W. Ramsey, Jane C. Davies, Noel G. McElvaney, New England Journal of Medicine	2011	2.1K
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i> Claire Wainwright, J.S. Elborn, Bonnie W. Ramsey, New England Journal of Medicine	2015	1.6K
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation Frank J. Accurso, Steven M. Rowe, John P. Clancy, New England Journal of Medicine	2010	798
Effect of High-Dose Ibuprofen in Patients with Cystic Fibrosis Michael W. Konstan, Pamela J. Byard, Charles L. Hoppel, New England Journal of Medicine	1995	734
Inflammatory cytokines in cystic fibrosis lungs. Tracey L. Bonfield, James R. Panuska, Michael W. Konstan, American Journal of Respiratory and Critical Care Medicine InflammationInflammatory CytokinesFibrosisInflammatory Lung DiseaseLung Inflammation	1995	704
Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Michael W. Konstan, Kathleen A. Hilliard, Tonya M. Norvell, American Journal of Respiratory and Critical Care Medicine AsthmaInflammatory Lung DiseaseLung InflammationImmunologyPediatric Lung Disease	1994	515
Genetic Modifiers of Lung Disease in Cystic Fibrosis Mitchell L. Drumm, Michael W. Konstan, Mark Schluchter, New England Journal of Medicine	2005	493
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation John P. Clancy, Steven M. Rowe, Frank J. Accurso, Thorax	2011	493
Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis Michael W. Konstan, Wayne J. Morgan, Steven M. Butler, The Journal of Pediatrics Advanced Lung DiseaseVentilationPediatricsForced Expiratory VolumePulmonary Physiology	2007	437
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial Michael Boyle, Scott C. Bell, Michael W. Konstan, The Lancet Respiratory Medicine PathologyCftr CorrectorPulmonary FibrosisMedicinePhe508del Cftr Mutation	2014	436

Page 1